Verona Pharma Plc (VRNA) - News Archive

April 9, 2025Today’s stock market rally is marked by significant gains across a range of industries, buoyed by promising economic data and investor optimism. Here’s a breakdown of the sectors driving...

April 9, 2025 – Market activity took a downturn on Wednesday, April 9, 2025, as investors processed a combination of mixed earnings reports and concerning labor statistics. Major indices fell amid co...

: The launch of Ohtuvayre by Verona Pharma marks a notable achievement in the realm of respiratory medications. This article examines the successful market introduction of Ohtuvayre, alongside presenting highlights of V...

Verona Pharma Plc, a rising star in respiratory therapeutics, is set to present a comprehensive suite of findings from its successful Phase 3 ENHANCE studies involving Ohtuvayre, a novel treatment for Chronic Obstructiv...

Verona Pharma s Ohtuvayre (ensifentrine) Receives FDA Approval for COPD Maintenance Treatment, Boosting Revenue ProspectsVerona Pharma Plc, a renowned biopharmaceutical company, has recently achieved a significant miles...

Verona Pharma, the cutting-edge biopharmaceutical company at the cusp of reinventing therapeutic practices, has inked a historic deal involving a strategic $650 million financing package. This astounding boost comes cou...

Verona Pharma Plc, a leading biopharmaceutical company specializing in the development of innovative respiratory medicines, has recently announced the appointment of Mr. Andrew Fisher as their new General Counsel. This...

Verona Pharma Plc, a prominent player in the pharmaceutical industry, has recently announced strategic moves to strengthen its financial position, enabling continued growth. Despite a minor increase in borrowings, Veron...